The company, a provider of patient-centric data analytics made the announcement today (February 6), that this unparalleled volume of data will allow sponsors to access data on patients with more than 4,000 indications, plan more successful trials, and stimulate clinical development activity with a high degree of accuracy.
The company says that with such a huge repository of data in Trial Accelerator, it has now published the second edition of its Digital Patient Profile (DPP) catalog. Each DPP delivers a statistical view of patient attributes to improve protocol design and accelerate the adoption of digital trial arms.
The new DPPs are called Relapsed/ Refractory Follicular Lymphoma, CDKL5, Chronic Migraine, Episodic Migraine, Stroke – Acute Ischemic, and Acute Coronary Syndrome.
Wealth of data for sponsors
“Collating data from 100 million patients is a huge milestone for Phesi. For almost two decades we have been gathering and structuring a wealth of data for sponsors and clinical trial planners,” said Dr Gen Li, President, Phesi.
“Context is key: Phesi can identify where and when specific data was generated, by whom (study investigators), and how (study design) to provide contextualized data that delivers precision, insights, and certainty to clinical development teams. We are committed to continuing to innovate and support our clients to make breakthroughs, and deliver smarter cures to patients, faster.”
The second edition of the Digital Patient Profile catalog contains granular patient data across 34 indications both at cohort level and patient level. The profiles will be used by sponsors to develop Digital Twins and Digital Trial Arms as part of clinical development strategies.
DPPs also support the wider adoption of single-arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts. As well as 12 oncology profiles, the catalogue will cover 22 other prevalent diseases. The addition of stroke is particularly crucial, with Phesi’s recent analysis of all clinical trials in 2023 finding that stroke is now the third most-studied disease area worldwide.
Popularity of digital twins increasing
“We are continually refining the methodology by which we create patient profiles,” explained Jonathan Peachey, COO and board director, Phesi.
“In this way, we empower sponsors to make data-led decisions in the trial planning process, as well as enabling them to use digital twins and the next generation of digital control arms. We’ve seen the popularity of digital twins increase, but tools like the Digital Patient Profile are what make these twins a reality.”
Phesi says the traditional data management function of collecting and interpreting patient data from clinical trials is transforming. Digitalized patient data can be used to enhance or even replace those collected from clinical trials.
The company says its Trial Accelerator delivers these advances directly to its users. The latest updates to the platform represent an accumulation of almost 20 years’ worth of effort collating data from product and disease registries, data from electronic health records, medical claims data, and data gathered from almost 100,000 dynamically updated sources. A global patent was granted in Dec 2023 from the Japanese Patent Office for Phesi’s method and system of analyzing and optimizing clinical trial protocols; including protocol design optimization and minimizing avoidable protocol amendments.
